Detalles de la búsqueda
1.
Panitumumab plus trifluridine/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial.
Int J Cancer
; 153(8): 1520-1528, 2023 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37391938
2.
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer.
Biomedicines
; 12(4)2024 Apr 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38672164
3.
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials.
Cancers (Basel)
; 15(7)2023 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37046778
4.
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.
JAMA Oncol
; 9(7): 966-970, 2023 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37200022
5.
Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial.
JAMA Oncol
; 7(10): 1529-1535, 2021 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34382998
6.
Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience.
Cancers (Basel)
; 11(10)2019 Oct 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31597339
Resultados
1 -
6
de 6
1
Próxima >
>>